OBI Pharma, Inc. (4174.TWO)
| Previous close | 60.30 |
| Open | 60.30 |
| Bid | 60.20 x 0 |
| Ask | 60.80 x 0 |
| Day's range | 60.00 - 60.80 |
| 52-week range | 59.40 - 99.30 |
| Volume | |
| Avg. volume | 445,629 |
| Market cap | 13.938B |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.57 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireOBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platformTAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC). When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior PK/PD properties, and a favorable safety profile across various preclinical animal
- GlobeNewswire
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody - drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024.TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2 study of its novel antibody
